ABVC - CIK 0001173313
ABVC BIOPHARMA, INC. trades as ABVC. In its fiscal 2024 annual report the company posted revenue of $509.59K, up 234.3% from the prior year and net income of -$7.91M. This page tracks ABVC BIOPHARMA, INC. through 780 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 11 fiscal years ABVC BIOPHARMA, INC.'s revenue grew from $7.79K to $509.59K, a compound annual growth rate of 46.2%. Net profit margin expanded from -87184.2% to -962.1% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-18 |
| NT 10-Q | - | 2026-05-15 |
| POS AM | - | 2026-03-27 |
| Major company event | 8-K | 2026-03-27 |
| Proxy statement | DEF 14A | 2026-03-05 |
| Annual report | 10-K | 2026-03-03 |
| Quarterly report (amended) | 10-Q/A | 2026-03-03 |
| Major company event | 8-K | 2026-03-03 |
The largest companies sharing ABVC BIOPHARMA, INC.'s SEC industry classification (pharmaceutical preparations).
ABVC BIOPHARMA, INC. reported revenue of $509.59K for fiscal year 2024, an increase of 234.3% year over year.
In its latest fiscal year ABVC BIOPHARMA, INC. reported a net loss of $7.91M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.